Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Racotumomab plus best supportive treatment versus best supportive treatment alone in advanced non-small cell lung cancer
ISRCTN47153584Phase 4Completed
- Sponsor
- Recombio
- Start
- Dec 2009
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, open-label trial of racotumomab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Recombio. Primary endpoints: Overall survival in the overall study population and Overall survival in stage IIIA and dry IIIB subgroup. Started Dec 2009; status: completed.
02
Drugs
racotumomab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN47153584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47153584.